{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:37:04Z","timestamp":1792597024416,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T00:00:00Z","timestamp":1275004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00415-010-5603-7","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T08:45:41Z","timestamp":1274949941000},"page":"1682-1685","source":"Crossref","is-referenced-by-count":54,"title":["Zonisamide in managing impulse control disorders in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"257","author":[{"given":"Pedro Emilio","family":"Bermejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ruiz-Huete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buenaventura","family":"Anciones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,28]]},"reference":[{"key":"5603_CR1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D et al (2009) Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord 24:1561\u20131570","journal-title":"Mov Disord"},{"issue":"suppl","key":"5603_CR2","first-page":"456","volume":"30","author":"R Ceravolo","year":"2009","unstructured":"Ceravolo R, Frosini D, Rossi C et al (2009) Prevalence of impulse control disorders in Parkinson\u2019s disease. Neurol Sci 30(suppl):456","journal-title":"Neurol Sci"},{"key":"5603_CR3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2007.11.008","volume":"14","author":"PE Bermejo","year":"2008","unstructured":"Bermejo PE (2008) Topiramate in managing impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord 14:448\u2013449","journal-title":"Parkinsonism Relat Disord"},{"key":"5603_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eplepsyres.2007.04.007","volume":"75","author":"M Baulac","year":"2007","unstructured":"Baulac M, Leppik IE (2007) Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 75:75\u201383","journal-title":"Epilepsy Res"},{"key":"5603_CR5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e318170577f","volume":"32","author":"PE Bermejo","year":"2009","unstructured":"Bermejo PE, Dorado R (2009) Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol 32:103\u2013106","journal-title":"Clin Neuropharmacol"},{"key":"5603_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1526-4637.2005.05035.x","volume":"6","author":"A Atli","year":"2005","unstructured":"Atli A, Dogra S (2005) Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med 6:225\u2013234","journal-title":"Pain Med"},{"key":"5603_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.33588\/rn.4603.2007523","volume":"46","author":"PE Bermejo","year":"2008","unstructured":"Bermejo PE, Ruiz-Huete C, Dorado R et al (2008) Zonisamida en el temblor esencial refractario. Rev Neurol 46:139\u2013142","journal-title":"Rev Neurol"},{"key":"5603_CR8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01365.x","volume":"61","author":"G Kinrys","year":"2007","unstructured":"Kinrys G, Vasconcelos e Sa D, Nery F (2007) Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61:1050\u20131053","journal-title":"Int J Clin Pract"},{"key":"5603_CR9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1381612043453180","volume":"10","author":"M Murata","year":"2004","unstructured":"Murata M (2004) Novel therapeutic effects on the anticonvulsant, zonisamide on Parkinson\u2019s disease. Curr Pharm Des 10:687\u2013693","journal-title":"Curr Pharm Des"},{"key":"5603_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"M Murata","year":"2006","unstructured":"Murata M, Hasegawa K, Kanazawa I (2006) Zonisamide improves motor function in Parkinson disease. A double-blind study. Neurology 68:45\u201350","journal-title":"Neurology"},{"key":"5603_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1756285609338501","volume":"2","author":"PE Bermejo","year":"2009","unstructured":"Bermejo PE, Anciones B (2009) A review of the use of zonisamide in Parkinson\u2019s disease. Ther Adv Neurol Disord 2:313\u2013317","journal-title":"Ther Adv Neurol Disord"},{"key":"5603_CR12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/mds.21717","volume":"22","author":"PE Bermejo","year":"2007","unstructured":"Bermejo PE (2007) Zonisamide in patients with essential tremor and Parkinson\u2019s disease. Mov Disord 22:2137\u20132138","journal-title":"Mov Disord"},{"key":"5603_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","volume":"23","author":"E Mamikonyan","year":"2008","unstructured":"Mamikonyan E, Siderowf AD, Duda JE et al (2008) Long-term follow-up of impulse control disorders in Parkinson\u2019s disease. Mov Disord 23:75\u201380","journal-title":"Mov Disord"},{"key":"5603_CR14","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","volume":"21","author":"C Ardouin","year":"2006","unstructured":"Ardouin C, Voon V, Worbe Y et al (2006) Pathological gambling in Parkinson\u2019s disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21:1941\u20131946","journal-title":"Mov Disord"},{"key":"5603_CR15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","volume":"61","author":"E Driver-Dunckley","year":"2003","unstructured":"Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease. Neurology 61:422\u2013423","journal-title":"Neurology"},{"key":"5603_CR16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","volume":"66","author":"V Voon","year":"2006","unstructured":"Voon V, Hassan K, Zurowski M et al (2006) Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology 66:1750\u20131752","journal-title":"Neurology"},{"key":"5603_CR17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1345\/aph.1A412","volume":"36","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2002","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Sayed Y, Garc\u00eda-Soldevilla MA (2002) Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36:1178\u20131179","journal-title":"Ann Pharmacother"},{"key":"5603_CR18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002826-200105000-00009","volume":"24","author":"U Gschwandtner","year":"2001","unstructured":"Gschwandtner U, Aston J, Renaud S et al (2001) Pathologic gambling in patients with Parkinson\u2019s disease. Clin Neuropharmacol 24:170\u2013172","journal-title":"Clin Neuropharmacol"},{"key":"5603_CR19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K et al (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423\u2013428","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5603_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","volume":"163","author":"JE Grant","year":"2006","unstructured":"Grant JE, Potenza MN, Hollander E et al (2006) Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163:303\u2013312","journal-title":"Am J Psychiatry"},{"key":"5603_CR21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/01.wnl.0000243252.71365.81","volume":"67","author":"KJ Black","year":"2006","unstructured":"Black KJ, Friedman JH (2006) Repetitive and impulsive behaviours in treated Parkinson disease. Neurology 67:1118\u20131119","journal-title":"Neurology"},{"key":"5603_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1353-8020(09)70847-8","volume":"15","author":"R Ceravolo","year":"2009","unstructured":"Ceravolo R, Frosini D, Rossi C et al (2009) Impulse control disorders in Parkinson\u2019s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 15:111\u2013115","journal-title":"Parkinsonism Relat Disord"},{"key":"5603_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(87)90168-5","volume":"413","author":"CL Schauf","year":"1987","unstructured":"Schauf CL (1987) Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 413:185\u2013188","journal-title":"Brain Res"},{"key":"5603_CR24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","volume":"30","author":"V Biton","year":"2007","unstructured":"Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30:230\u2013240","journal-title":"Clin Neuropharmacol"},{"key":"5603_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","volume":"5","author":"M Kito","year":"1996","unstructured":"Kito M, Maehara M, Watanabe K (1996) Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5:115\u2013119","journal-title":"Seizure"},{"key":"5603_CR26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1212\/WNL.60.1.147","volume":"60","author":"JT Chen","year":"2003","unstructured":"Chen JT, Garcia PA, Alldredge BK (2003) Zonisamide-induced restless legs syndrome. Neurology 60:147","journal-title":"Neurology"},{"key":"5603_CR27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/mds.21717","volume":"22","author":"PE Bermejo","year":"2007","unstructured":"Bermejo PE, Zabala JA, Saez R (2007) Restless legs syndrome induced by zonisamide. Mov Disord 22:1517\u20131518","journal-title":"Mov Disord"},{"key":"5603_CR28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/00952991003674812","volume":"36","author":"CM Knapp","year":"2010","unstructured":"Knapp CM, Sarid-Segal O, Richardson MA et al (2010) Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 36:102\u2013105","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5603-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-010-5603-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5603-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:42:36Z","timestamp":1740123756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-010-5603-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,28]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["5603"],"URL":"https:\/\/doi.org\/10.1007\/s00415-010-5603-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,28]]}}}